Page last updated: 2024-10-15

npt 15392

Description

NPT 15392: RN given refers to unlabeled parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135474265
CHEMBL ID2304038
MeSH IDM0087053

Synonyms (22)

Synonym
npt-15392
nosantine
npt 15392
6h-purin-6-one, 1,9-dihydro-9-(1-(1-hydroxyethyl)heptyl)-, (r*,s*)-
erythro-9-(1-(1-hydroxyethyl)heptyl)hypoxanthine
nosantinum [latin]
erythro-9-(2-hydroxy-3-nonyl)hypoxanthine
erythro-9-(2-hydroxy-3-nonyl)-1,9-dihydro-6h-purin-6-one
(r*,s*)-1,9-dihydro-9-(1-(1-hydroxyethyl)heptyl)-6h-purin-6-one
nosantina [spanish]
nosantine [inn:ban]
unii-nym432g79c
nosantinum
nym432g79c ,
nosantina
76600-30-1
nosantine [inn]
CHEMBL2304038
9-[(2r,3s)-2-hydroxynonan-3-yl]-3h-purin-6-one
cid 10333790
Q27285111
9-[(2r,3s)-2-hydroxynonan-3-yl]-1h-purin-6-one

Actions

NPT 15392 does not enhance or alter the number of clonable B cells. It was able to enhance PHA-induced IL-2 production at 10-100 times lower concentrations than isoprinosine.

ExcerptReference
"NPT 15392 does not enhance or alter the number of clonable B cells."( Immunoenhancing activity of NPT 15392: a potential immune response modifier.
Faanes, RB; Hadden, JW; Merluzzi, VJ; Susskind, B; Walker, MM; Williams, N, 1982
)
"NPT 15392 was able to enhance PHA-induced IL-2 production at 10-100 times lower concentrations than isoprinosine."( Effects of isoprinosine and NPT 15392 on interleukin-2 (IL-2) production.
Hadden, JW; Wiranowska-Stewart, M, 1986
)

Treatment

ExcerptReference
"Rats treated with NPT 15392 had significantly enhanced DTH reactions at the 0.1 mg/kg dose."( The selectivity of isoprinosine, NPT 15392, avridine and cyclophosphamide on multiple immune responses in rats.
Exon, JH; Henningsen, GM; Koller, LD; Talcott, PA, 1986
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-199023 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.17%)5.53%
Reviews5 (20.83%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (75.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]